matter for debate
the royal colleges of surgeons of edinburgh and ireland | 325 © 2008 Surgeon 6; 6: 325-8
Health Protection
Surveillance Centre, Dublin
Department of Clinical
Microbiology, Beaumont
Hospital, Dublin, Ireland
Correspondence to:
Dr. Fidelma Fitzpatrick,
Health Protection
Surveillance Centre,
25-27 Middle Gardiner Street,
Dublin 1, Ireland
Tel: +353 1 8765300
Fax: +353 1 8561299
Email: delma.tzpatrick@
hse.ie
F. Fitzpatrick
keywords: clostridium difficile, surgery
Surgeon, 1 December 2008, pp. 325-8
MANAGEMENT OF CLOSTRIDIUM
DIFFICILE INFECTION – MEDICAL
OR SURGICAL?
C. difficile infection (CDI) typically presents as diar-
rhoea, abdominal cramps, fever and leucocytosis,
occurring several days to up to 10 weeks after anti-
biotic therapy. Pseudomembranous colitis (PMC)
is the most severe manifestation and is usually a
pancolitis, although a right-sided colitis is also
described. Severely ill patients may have little or
no diarrhoea due to dilation of the colon (toxic
megacolon) and paralytic ileus that may result from
a loss of colonic muscular tone. CDI-associated
mortality varies with the population under study
and has been reported as high as 30%, although
attributable mortality is thought to be lower.
1,2
Te
most common risk factors for CDI are exposure
to antibiotics, advanced age and hospitalisation.
Te disease is particularly linked with the use of
broad-spectrum antibiotics; however, nearly all
other antibiotics have been associated with CDI.
3
Te most commonly implicated are clindamycin,
the broad-spectrum cephalosporins and fluroqui-
nolones. While CDI is a disease predominantly of
older patients, other risk factors such as hospitalisa-
tion, recent gastrointestinal surgery or procedures
and immunosuppressive therapy can also predis-
pose to infection. Another proposed risk factor is
exposure to proton pump inhibitors – it is thought
that the increased gastric pH produced by these
drugs leads to decreased destruction of spores.
4,5
However, this association has not been demon-
strated in other studies.
6,7
In Canada, a changing
pattern of CDI severity was observed from 1991
to 2003.
8
Te number of patients with compli-
cated CDI (defined as having any of megacolon,
perforation, colectomy, shock requiring vasopressor
therapy, or death) rose significantly from around
7% in 1991-1992 to 18% in 2003. Te epidemic
was largely due to the emergent hyper-virulent
strain PCR ribotype 027.
9
C. difficile ribotype 027
outbreaks have been described in many European
countries and recently, the first case of C. difficile
ribotype 027 in Ireland was reported.
2,10
C. difficile
ribotype 027 produces 23 and 16 times more toxins
B and A than previously described C. difficile strains
and is associated with fluoroquinolone resistance
in vitro.
3
Tis editorial will discuss the clinical
management of CDI, including the evidence
for surgical management.
Diagnosis of CDI
All patients in whom a diagnosis of gastrointestinal
infection is suspected should have a stool specimen
sent for microbiological analysis. Te diagnosis of
CDI is usually made by detection of C. difficile
toxins by enzyme immunoassay (EIA). Te main
advantage of these assays is rapid same day results.
A wide variety of commercial EIAs exist which
generally perform well with regard to specificity;
however, recent studies demonstrate that they have
significantly reduced sensitivity (65-85%).
11,12
Tis
low sensitivity can lead to increased reporting of
false negative results, subsequently presenting prob-
lems with clinical diagnosis and infection control.
In cases where CDI is clinically suspected and
EIA results are negative, the laboratory should be
informed, in order to perform culture on the speci-
men. In addition, CT can be a useful adjunct. CT
findings in severe CDI may include colonic thick-
ening and pericolonic stranding and can predict
intra-operative findings.
13-15
Management of
C. difficile infection
1. Isolation of the patient and infection control
precautions
Prompt isolation in a single room with clinical hand
washing sink and en suite facilities using standard
and contract precautions is recommended for all
patients with known or suspected CDI.
16
Hands
should be washed before and after each contact
with the patient and/or patient equipment with
soap (antimicrobial or non-antimicrobial) and
water.
17
None of the agents (including alcohols,